Isogenica publishes whitepaper on VHH in T cell redirection
Learnings from the safety and efficacy of current T-cell antibody engagers and CAR-T in clinical use and development have provided a foundation to create enhanced next-generation treatments. Significant possibilities exist to optimise both BiTEs and CAR-T through the incorporation of humanised camelid-derivedsingle domain antibodies. VHH represent an attractive construct for incorporation in CAR-T and T-cell engaging therapeutic format with carefully designed affinities, valencies and specificities enabling refined tumour cell targeting and modes of action.
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities.
Who should read this
Research leaders and principal investigators in biopharmaceutical and academic research centres.
Corporate leaders and business development executives in the biopharmaceutical sector.